The director of the Kansas City Multiple Sclerosis Center at College Park Neurology, discusses goals of therapy in patients with relapsing multiple sclerosis, especially for the subset of patients in which steroids are not an option or are ineffective.
Elizabeth Thiele, MD, PhD, reviews long-term safety and efficacy data on the use of cannabidiol for children and young adults with Dravet or Lennox-Gastaut syndromes as revealed through an open-label extension study, GWPCARE5, presented at the AAN 2020 Annual Meeting.
The staff neurologist, Vice-Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute detailed his experience managing patients with various conditions through a telemedicine platform.
A discussion on best practices of patients with optic neuritis who present with brain lesions and a pivotal MRI trial and its impact on the treatment paradigm.
The professor of neurology at NYU Langone shares her thoughts on the clinical data that has been released so far on patients with COVID-19.
Jiwon Oh, MD, PhD, discusses recent recommendations by the National Multiple Sclerosis Society on the use of disease-modifying therapies to treat MS during the coronavirus pandemic.
Practical advice on the administration of on-demand therapies, including tips and tricks for using levodopa inhalation powder for off episodes of Parkinson disease.
The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.
SAP Partner Banner